{‘She has zero qualifications’: the American medical community braces for Tracy Beth Høeg’s tenure at the Food and Drug Administration.

As America undertakes sweeping changes to its vaccination schedules, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by expressing skepticism about Covid vaccinations during the global health crisis and has concentrated on potential deaths after Covid vaccination in her short position at the Food and Drug Administration.

Planned Shifts to Childhood Vaccine Schedule

Health officials were set to announce sweeping revisions to the pediatric vaccination calendar recently, aligning the US with the Danish vaccine program, according to reports – a substantial departure that would put the US out of alignment with much of the global community with no evidence for benefit. The announcement has been delayed until the new year.

Instead of the director of the vaccine center, Dr. Høeg is listed to present at the gathering. She was newly appointed interim head of the FDA’s CDER, the fifth person to lead the division this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a greater focus upon rolling back previously authorized immunizations at the FDA.

Høeg has often pushed for discontinuing some childhood vaccine recommendations in the US in order to be more like Denmark, a nation with universal health coverage and a population approximately the population of the state of Wisconsin.

So far statements, she has persisted in emphasizing on vaccines – typically the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Expertise

Dr. Høeg has no apparent track record in pharmaceutical research, regulation or administrative roles, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for overseeing the CDER, said a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in leading a major agency. She lacks background in pharmaceutical oversight.”

Past commissioners of CBER would “understand laws and regulations and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that former directors who ran the center have had.”

The drug center has an immense workload at the FDA, the former commissioner pointed out.

“The public just pays attention on the novel medication approvals, but the off-patent medication office clears a multitude of generic medications. There is also a biologic copycat branch, over-the-counter program and more, and every single one have to be looked after,” she said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major leadership aspect to the role, which manages over 5,000 employees. “It’s a enormous administrative position, if you do it right,” Woodcock added.

Agency Reaction and Contentious Initiatives

In response to inquiries about Høeg’s fitness for the role and whether this assignment indicates greater collaboration among regulatory chiefs on vaccines, a spokesperson stated that the “inquiries are based on inaccurate presumptions”.

“Her experience aligns with the functions of her position,” the spokesperson said, pointing to the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the agency head's new expedited review system, a contentious rapid medication authorization process that apparently concerned her predecessors. “How are these therapies being selected for this voucher program? Who is making the choices?” Dr. Howard said. “There’s a lot of confidentiality occurring at the agency right now.”

Overall, he stated, “the Food and Drug Administration appears to be shifting towards less stringent regulations of most medications, with the exception of vaccines.”

Established Track Record on Vaccines

With immunizations, Høeg has a more established, if problematic, history, Howard observe. She authored a study using unverified volunteer-provided data to estimate the incidence of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccines are riskier than they are.

Among her “desired changes” for the new administration featured changing regulations for recently developed shots and discontinuing “optional” vaccines, she remarked after the election on a online show. At the FDA, Høeg has allegedly proposed excluding adolescent males from receiving Covid vaccines.

“She is an all-around dogmatist who begins with her conclusions and works backwards to fit the science in a highly deceptive, fraudulent manner,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with fellow contrarians, {like|